Prevention of venous thromboembolism in the orthopedic surgery patient

Cleveland Clinic Journal of Medicine

Volumn 75, Issue SUPPL.3, 2008, Pages 27-36

  Deitelzweig, Steven B ^a   Brotman, Daniel J ^b   Mckean, Sylvia C ^b   Jaffer, Amir K ^b   Amin, Alpesh N ^b   Spyropoulos, Alex C ^b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; POLYSACCHARIDE; WARFARIN;

HUMAN; ORTHOPEDIC SURGERY; POSTOPERATIVE COMPLICATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; ORTHOPEDIC PROCEDURES; POLYSACCHARIDES; POSTOPERATIVE COMPLICATIONS; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 46349095882     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.75.Suppl_3.S17     Document Type: Article

References (37)

1. Yu HT, Dylan ML, Lin J, Dubois RW. Hospitals' compliance with prophylaxis guidelines for venous thromboembolism. Am J Health Syst Pharm 2007; 64:69-76.
2. Stratton MA, Anderson FA, Bussey HI, et al. Prevention of venous thromboembolism: adherence to the 1995 ACCP consensus guidelines for surgical patients. Arch Intern Med 2000; 160:334-340.
3. National Consensus Standards for Prevention and Care of Venous Thromboembolism (VTE). The Joint Commission Web site. http://www.jointcommission.org/PerformanceMeasurement/PerformanceMeasurement/VTE.htm. Accessed January 8, 2008.
4. Surgical Care Improvement Project. MedQIC Web site. http://www.medqic.org/scip/. Accessed January 8, 2008.
5. SCIP process and outcome measures, October 2005. MedQIC Web site. http://www.medqic.org. Accessed January 1, 2007.
6. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl):338S-400S.
7. Zimlich RH, Fulbright BM, Friedman RJ. Current status of anticoagulation therapy after total hip and total knee arthroplasty.J Am Acad Orthop Surg 1996; 4:54-62.
8. Planes A, Vochelle N, Mazas F, et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988; 60:407-410.
9. Colwell CW Jr, Spiro TE, Trowbridge AA, et al. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Clin Orthop Relat Res 1995; 321:19-27.
10. Bauer KA, Eriksson BI, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345:1305-1310.
11. Turpie AGG. Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice. Am Heart J 2001; 142(Suppl):S9-S15.
12. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120:897-902.
13. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335:540-546.
14. Samsa GP, Matchar DB, Goldstein LB, et al. Quality of anticoagulation management among patients with atrial fibrillation: review of medical records from 2 communities. Arch Intern Med 2000; 160:967-973.
15. PEP Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355:1295-1302.
16. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haemotol 2003; 121:535-555.
17. Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital lowmolecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001; 135:858-869.
18. Haentjens P, De Groote K, Annemans L. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement: a cost-utility analysis. Arch Orthop Trauma Surg 2004; 124:507-517.
19. Colwell CW Jr, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999; 81:932-940.
20. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. Arch Intern Med 2000; 160:2199-2207.
21. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism after knee arthroplasty: a randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996; 124:619-626.
22. Fitzgerald RH Jr, Spiro TE, Trowbridge AA, et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty: a randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg Am 2001; 83-A:900-906.
23. Eriksson BI, Bauer KA, Lassen MR, Turpie AG, Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345:1298-1304.
24. Demers C, Marcoux S, Ginsberg JS, Laroche F, Cloutier R, Poulin J. Incidence of venographically proved deep vein thrombosis after knee arthroscopy. Arch Intern Med 1998; 158:47-50.
25. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001; 119(1 Suppl):132S-175S.
26. Brotman DJ, Jaffer AK, Hurbanek JG, Morra N. Warfarin prophylaxis and venous thromboembolism in the first 5 days following hip and knee arthroplasty. Thromb Haemost 2004; 92:1012-1017.
27. Eriksson BI, Lassen MR; Pentasaccharide in Hip-Fracture Surgery Plus Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003; 163:1337-1342.
28. The Botticelli Investigators. Late-breaking clinical trial: a dose-finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis [abstract]. Presented at the 21st Congress of the International Society on Thrombosis and Haemostasis; July 2007; Geneva, Switzerland.
29. Fisher WD, Eriksson BI, Bauer KA, et al. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost 2007; 97:931-937.
30. Haas S. New oral Xa and IIa inhibitors: updates on clinical trial results. J Thromb Thrombolysis 2008; 25:52-60.
31. Friedman RJ, Caprini JA, Comp PC, et al. Dabigatran etexilate vs enoxaparin in preventing venous thromboembolism following total knee arthroplasty. Presented at: 2007 Congress of the International Society on Thrombosis and Haemostasis; July 7-13, 2007; Geneva, Switzerland.
32. Committee for Medicinal Products for Human Use summary of positive opinion for Pradaxa [news release]. London, UK: European Medicines Agency. January 24, 2008. http://www.emea.europa.eu/pdfs/human/opinion/Pradaxa_3503008en.pdf. Accessed February 21, 2008.
33. Goldhaber SZ, Grodstein F, Stampfer MJ. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997; 277:642-645.
34. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR, for the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. Arch Intern Med 2002; 162:1833-1840.
35. Stein PD, Beemath A, Matta F, et al. Clinical characteristics of patients with acute pulmonary embolism: data from PIOPED II. Am J Med 2007; 120:871-879.
36. Goldhaber SZ. Diagnosis of acute pulmonary embolism: always be vigilant. Am J Med 2007; 120:827-828.
37. American Academy of Orthopaedic Surgeons Clinical Guideline on Prevention of Symptomatic Pulmonary Embolism in Patients Undergoing Total Hip or Knee Arthroplasty: Summary of Recommendations. http://www.aaos.org/Research/guidelines/PE_summary.pdf. Accessed December 10, 2007.